伯基特淋巴瘤的治疗：单药化疗与联合化疗的随机临床试验

Treatment of Burkitt's lymphoma: randomized clinical trial of single-agent versus combination chemotherapy.

作者信息

Olweny C L, Katongole-Mbidde E, Kaddu-Mukasa A, Atine I, Owor R, Lwanga S, Carswell W, Magrath I T

出版信息

Int J Cancer. 1976 Apr 15;17(4):436-40. doi: 10.1002/ijc.2910170404.

Abstract

A randomized clinical trial designed to compare the effectiveness of cytoxan (CTX) alone versus a combination consisting of CTX, vincristine (Oncovin) and methotrexate (COM) in the treatment of Burkitt's lymphoma (BL) was carried out. Nineteen patients were selected at random to receive CTX alone while 21 received COM. The two treatment regimens were equally effective in inducing remissions, and complete response rates of 83.3% and 84.3% were observed for CTX- and COM-treated patients, respectively. The relapse frequencies were also equal but the pattern of relapse was clearly different. Seven out of 8 (87.5%) in the CTX group relapsed with systemic and central nervous system (CNS) tumor, while 8 out of 10 (80%) in the COM group relapsed with CNS disease only. This difference is highly significant p = 0.008. The remission durations and survival to date are the same.

摘要

开展了一项随机临床试验，旨在比较单独使用环磷酰胺（CTX）与由环磷酰胺、长春新碱（Oncovin）和甲氨蝶呤组成的联合方案（COM）治疗伯基特淋巴瘤（BL）的有效性。随机选择19例患者单独接受CTX治疗，21例接受COM治疗。两种治疗方案在诱导缓解方面同样有效，接受CTX和COM治疗的患者的完全缓解率分别为83.3%和84.3%。复发频率也相同，但复发模式明显不同。CTX组8例中有7例（87.5%）出现全身和中枢神经系统（CNS）肿瘤复发，而COM组10例中有8例（80%）仅出现CNS疾病复发。这种差异具有高度显著性（p = 0.008）。缓解持续时间和迄今为止的生存率相同。